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Abstract
Background: Gliomas are aggressive tumors of the central nervous system that rely on production of growth
factors for tumor progression. Interleukin 8 (IL-8) is up-regulated in gliomas to promote angiogenesis and
proliferation. The aim of this study was to evaluate the association of the IL-8 -251 T/A and +781 C/T polymorphisms
and glioma risk.
Methods: We enrolled 300 glioma patients and 300 age- and gender-matched healthy controls. A prospective
hospital-based case–control design and logistic regression analysis were utilized. The IL-8 gene polymorphisms were
genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: Glioma patients had a significantly higher frequency of IL-8 -251 AA genotype [odds ratio (OR) =1.91, 95 %
confidence interval (CI) = 1.22, 3.00; P = 0.005] and IL-8 -251 A allele (OR =1.36, 95 % CI = 1.08, 1.70; P = 0.009) than
controls. When stratified by the grade of glioma, patients with WHO IV glioma had a significantly higher frequency of
IL-8 -251 AA genotype (OR =1.56, 95 % CI = 1.01, 2.39; P = 0.04).
Conclusions: To the best of our knowledge, this is the first report in the literature that the IL-8 -251 AA genotype and
A allele were at a higher risk for glioma.
Background
Gliomas make up about 30 % of all brain and central
nervous system tumors and 80 % of all malignant brain
tumors [1]. Despite the growing number of preclinical
and clinical trials focused on the treatment of malignant
gliomas, the prognosis for this disease remains grim [2–4].
Only rare familial syndromes and exposure to high thera-
peutic doses of ionizing radiation are known causes of gli-
oma [5]. Some other factors are also found to affect glioma
risk, such as: high levels of processed meat consumption
and obesity during adolescence [6, 7]. Recent research has
focused on identifying germline polymorphisms associated
with risk of glioma, and using molecular markers to classify
glial tumors into more homogenous groups [5, 8, 9].
Interleukin-8 (IL-8), which is best known for its
leukocyte chemotactic properties and associated role in
inflammatory and infectious diseases [10], is now known
to possess tumorigenic and proangiogenic properties as
well [11, 12]. IL-8 is encoded by the IL-8 gene located
on chromosome 4q13-21, consisting of four exons, three
introns, and the proximal promoter region [13]. Several
SNPs have been reported in the IL-8 gene and some of
them, such as −251 T/A (rs4073) and +781 C/T
(rs2227306), can regulate the IL-8 production [14–16].
In human gliomas, IL-8 is expressed and secreted at
high levels both in vitro and in vivo, and recent experi-
ments suggest it is critical to glial tumor neovascularity
and progression [12].
We hypothesized that common genetic variants in IL-8
gene influenced the risk of glioma. To test this hypothesis,
we performed a prospective hospital-based case–control
study to evaluate the association of the IL-8 -251 T/A
and +781 C/T polymorphisms and glioma risk.
Methods
Study population
In this prospective hospital-based case–control study,
we enrolled 300 glioma patients and 300 age- and
gender-matched healthy controls between May 2012 and
May 2014 in the Department of Neurosurgery, The First
Affiliated Hospital of Xi'an Jiao Tong University, China.
Tumor type and stage were determined according to the
WHO criteria [17]. In addition, similar to the cases the
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controls were all required to be born in China to native
Chinese Han parents. To confirm the diagnosis, two
physicians reviewed the hospital records and validated
each case. Collected clinical data included sex, age,
mean education, smoking, alcohol drinking and family
history of cancer. All data points were collected
through interviews with the patient or their families/
surrogates. All parts of the study were approved by the
Institutional Ethical Committee of the First Affiliated
Hospital of Xi'an Jiao Tong University, and informed
consent according to the Declaration of Helsinki was
obtained from all participants or their families/
surrogates.
DNA extraction and genotyping
Genomic DNA was isolated from white blood cells by
the commercially available Qiagen kit (QIAGEN Inc.,
Valencia, CA, USA). IL-8 -251 A/T and +781 C/T polymor-
phisms were determined by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP) as
previous described [18–20]. Restriction enzyme and primer
sequences of IL-8 promoter SNPs were listed in Table 1.
The PCR cycling conditions were 5 min at 94 °C followed
by 35 cycles of 1 min at 94 °C, 1 min at 61 °C, and 2 min at
72 °C, with a final step at 72 °C for 20 min. The PCR prod-
uct was subjected to digestion for 4 h with restriction en-
zyme at 37 °C. Electrophoresis in a 2.5 % agarose gel
followed by ethidium bromide staining and ultraviolet illu-
mination allowed detection of the alleles. For quality con-
trol, two independent observers, read all genotypes without
knowing about the case or control status. When replicate
quality control samples were evaluated, genotypes showed
100 % concordance.
Statistical analysis
Data are presented as means ± standard deviation (SD)
or as percentages for categorical variables. Differences
between continuous variables were assessed by Student’s
t test, while those between categorical variables were
evaluated using Pearson x2 test. The existence of differ-
ences in genotypic frequencies between groups were
assessed by means of Pearson x2 test and calculating the
odds ratio (OR) with the 95 % confidence intervals (CI).
Statistical significance was taken at nominal P-value < 0.05
for all comparisons. SAS version 9.1 (SAS Institute, Cary,
NC) was used for all statistical tests.
Results
Characteristics of participants
Characteristics of glioma cases and healthy controls were
presented in Table 2. No significant differences were
found between the glioma cases and healthy controls in
sex, age, mean education, smoking, alcohol drinking and
family history of cancer (Table 2). Among 300 glioma
cases, 223 cases had astrocytomas, 43 cases had ependy-
momas, 19 cases had oligodendrogliomas, and 15 cases
had mixed gliomas (Table 2). In these cases, 17 were
WHO grade I gliomas, 106 were WHO grade II gliomas,
76 were WHO grade III gliomas, and 101 were WHO
grade IV gliomas (Table 2).
IL-8 -251 T/A polymorphisms and glioma risk
Glioma patients had a significantly higher frequency of
IL-8 -251 AA genotype (OR =1.91, 95 % CI = 1.22, 3.00;
P = 0.005) and IL-8 -251 A allele (OR =1.36, 95 % CI =
1.08, 1.70; P = 0.009) than controls (Table 3). When
stratified by the grade of glioma, patients with WHO IV
glioma had a significantly higher frequency of IL-8 -251
AA genotype (OR =1.56, 95 % CI = 1.01, 2.39; P = 0.04)
(Table 4). When stratified by the histology of glioma,
there was no significant difference in the distribution of
each genotype (Table 4).
IL-8 + 781 C/T polymorphisms and glioma risk
No association was found between IL-8 + 781 C/T poly-
morphisms and glioma risk (Table 3).
Discussion
Recent research has focused on identifying germline
polymorphisms associated with risk of glioma. A study
by Zong et al. suggested that the Cyclin D1 gene G870A
polymorphism was a risk factor for the development of
glioma [21]. There was a potential decreased susceptibil-
ity to glioma in association with the XRCC1 Arg399Gln
polymorphism, especially in Asians [22]. Regulator of
telomere elongation helicase 1 (RTEL1) rs6010620 poly-
morphism was likely to be associated with increased gli-
oma risk [23]. A study by Yuan et al. suggested that
common variants in ERCC1 may contribute to suscepti-
bility to glioma, especially in Asians [24]. The AA geno-
type of ERCC1 C8092A might be associated with a
higher risk of adult glioma than the CA and CC ge-
notypes and that the risk allele of ERCC2 K751Q
confered a significant susceptibility to adult glioma,
especially in Asian populations [25]. Strong evidence
Table 1 Restriction enzyme and primer sequences of IL-8 SNPs
Gene and SNP Enzyme Forward primer Reverse primer Product
IL-8 -251 A/T MfeI 5′-TCATCCATGATCTTGTTCTAA-3′ 5′-GGAAAACGCTGTAGGTCAGA-3′ T/T: 542 bp; A/A: 450 bp, 92 bp
IL-8 + 781 C/T EcoRI 5′-CTCTAACTCTTTATATAGGAATT-3′ 5′-GATTGATTTTATCAACAGGCA-3′ T/T: 203 bp; C/C: 184 bp, 19 bp
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for the association between XRCC3 C18607T poly-
morphism and glioma risk was found in a meta-
analysis [26]. There was a significant association be-
tween EGF +61A > G polymorphism and glioma risk
among Asians [27]. The polymorphism of interleukin-
4 receptor alpha (IL-4Ralpha) rs1801275 played a pro-
tective role in the glioma pathogenesis, particularly
among Asians [28].
The IL-8 gene polymorphisms were also associated
with many other cancers. A recent prospective case–
control study found that IL-8 polymorphism was associ-
ated with ovarian cancer [29]. The IL-8 -251 AA geno-
type was at a higher risk for oral cancer in the
Caucasian population [30, 31]. The IL-8-251 TA or AA
genotype conferred risk of cardia gastric cancer in a
population in Southwestern China [32]. The IL-8 -251
AA genotype was associated with the overall risk of de-
veloping gastric cancer and may seem to be more sus-
ceptible to overall gastric cancer in Asian populations
[33]. The IL-8 -251 T/A polymorphism was associated
with lung cancer susceptibility in Asians and the −251 A
allele may increase risk of lung cancer in Asians [34]. A
HuGE review and meta-analysis based on 42 case–con-
trol studies found that -251A allele was susceptible in
the development of low-penetrance cancers [35]. Two
case–control studies found that IL-8 -251 T/A poly-
morphism was significantly associated with colorectal
cancer susceptibility risk [36, 37]. The IL-8-251 T/A
polymorphism was associated with breast cancer risk
[38]. A study found that IL-8 -251 T/A polymorphism
was associated with bladder cancer susceptibility and
outcome after bacillus Calmette-Guerin immunotherapy
in a northern Indian cohort [39].
The mechanisms of the IL-8 -251 AA genotype and A
allele as risk factors of glioma are still unclear. In human
gliomas, IL-8 is expressed and secreted at high levels
both in vitro and in vivo, and recent experiments suggest
it is critical to glial tumor neovascularity and progression
[12]. There is strong evidence that IL-8 secretion is asso-
ciated with glioma formation and malignant progression
[12]. The IL-8 -251A allele in a homozygous state has
been associated with increased expression of the IL-8 gene
[40, 41]. It is entirely plausible that the the IL-8 -251 AA
genotype and A allele will affect the risk of gliomas.
There is limitation that needs to be acknowledged and
addressed regarding the present study. First of all, these
results should be interpreted with caution because the
population was only from China, which reduces the pos-
sibility of confounding from ethnicity, so it does not per-
mit extrapolation of the results to other ethnic groups.
Second, this study is limited by its size and lack of repli-
cation. Additional large scale studies are needed to con-
firm this finding. Third, since controls were recruited
from those who came to hospitals for routine health
Table 2 Characteristics of glioma cases and healthy controls
Glioma Controls P
Number of subjects 300 300
Sex (Male/Female) 165/135 163/137 0.87
Age (years), (mean ± SD) 43.6 ± 9.1 44.1 ± 9.3 0.51
Mean education (years) 10.3 ± 2.3 10.5 ± 2.2 0.28
Smoking (Ever/Never) 124/176 118/182 0.62
Alcohol drinking (Ever/Never) 106/194 102/198 0.73











Table 3 Genotype and allele frequencies of IL-8 gene polymorphisms among glioma cases and healthy controls
Genotypes Glioma (%) Controls (%) OR (95 %CI) P
−251 TT 96 (32.0) 105 (35.0) 1.00 (Reference)
−251 TA 120 (40.0) 147 (49.0) 0.89 (0.62,1.29) 0.55
−251 AA 84 (28.0) 48 (16.0) 1.91 (1.22,3.00) 0.005
−251 T allele frequency 312 (52.0) 357 (59.5) 1.00 (Reference)
−251 A allele frequency 288 (48.0) 243 (40.5) 1.36 (1.08,1.70) 0.009
+781 CC 166 (55.3) 161 (53.7) 1.00 (Reference)
+781 CT 97 (32.3) 108 (36.0) 0.87 (0.61,1.24) 0.44
+781 TT 37 (12.3) 31 (10.3) 1.16 (0.69,1.96) 0.58
+781 C allele frequency 429 (71.5) 430 (71.7) 1.00 (Reference)
+781 T allele frequency 171 (28.5) 170 (28.3) 1.01 (0.79,1.30) 0.95
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examination, there was a certain risk of selection bias.
Finally, rare familial syndromes and exposure to high
therapeutic doses of ionizing radiation are known causes
of glioma, which were not explored in the present study.
Conclusion
To the best of our knowledge, this is the first report in the
literature that the IL-8 -251 AA genotype and A allele
were at a higher risk for glioma. Additional large scale
studies are needed to confirm this finding. Genetic risk
profiling has the potential to identify individuals who have
not yet had glioma develop but are at high risk. Analysis
of polymorphic variants will potentially provide a tool to
assess the risk of glioma decades before diagnosis. This
process provides ample opportunity to implement behav-
ioral and environmental changes.
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